AEHR surged 28% in a single day—is the turning point or overdrawn?

NEXT PICK · Market Insights

AEHR surged 28% in a single day—is the turning point or overdrawn?

Tuesday, July 21, 2026

A small semiconductor testing company with annual revenue of only $50 million was pushed to a market value of $3.2 billion; The stock price surged 27.86% in a single day, closing at $98.91, with a cumulative gain of about 501% over the past twelve months.

It trended today not because of a sudden contract or acquisition, but because last week's explosive quarterly report is being collectively revalued by Wall Street—multiple brokerages simultaneously raised their ratings and target prices, and a "historic single-day rebound" in small-cap AI and semiconductor stocks boosted AEHR together.

So here's the question

When a company has just given guidance to triple revenue, but its stock price has already risen fivefold, are you buying the starting point of a turning point, or the end point where others realize their profits?

Latest price $98.91 ▲ +27.86%

FY27 revenue guidance $130–150 million ▲ +160–200%

Price-to-Sales Ratio (TTM) About 64 times higher — Peers are only 5–12 times higher

A veteran who "does a health check" for chips sells equipment but locks in production lines

Aehr Test Systems was founded in 1977 and is headquartered in Fremont, California. It is a semiconductor equipment company focused on wafer-level testing and burn-in. It does not produce chips but performs extreme pre-market health checks for chips.

At its core is the FOX series—FOX-XP and FOX-NP can simultaneously test, age, and stabilize wafers up to 300mm, while FOX-CP focuses on low-cost monolithic solutions. The accompanying WaferPak contactors and DiePak carriers extend the test chain from the wafer all the way to the bare chip and module.

Income is made up of two parts

One-time equipment sales, plus contactor components that are repeatedly purchased like consumables. End-use applications are precisely positioned in high-growth sectors such as AI computing data centers, electric vehicles and charging stations, silicon carbide (SiC) and gallium nitride (GaN) power devices, and photonic devices.

Where does its irreplaceability come from? It's not monopoly, but "binding." Once a wafer fab restricts its testing process to a specific equipment platform, changing suppliers means redoing process validation, yield calibration, and production line shutdowns, costing months or even millions of dollars.

In other words, every FOX sold by AEHR is driving a hard-to-remove nail into the customer's production line. Thousands of systems have been installed worldwide, making it a moat in itself. But it is too small in size and too limited in category, so this moat is deep and not wide.

A company with a price-to-sales ratio of 64 times has just quietly turned a loss

Let's look at the contrast first

With a market cap of about $3.2 billion, corresponding to $50 million in FY2026 revenue, the static price-to-sales ratio is as high as about 64 times—while mature equipment vendors like Teradyne and Advantest typically only have 5 to 12 times.

But the old label of "continuously burning money" must be shed. In the FY2026 fourth quarter disclosed last week, revenue was $18.8 million, up 33% year-over-year, with GAAP net profit of $1.4 million, or $0.04 per share, turning losses into profits; The full-year non-GAAP report also barely posted a margin.

Cash flow has also been misinterpreted. After completing a round of equity issuance, the company held about $116.5 million in cash on hand, making short-term survival not a problem — the price was dilution of existing shareholders.

The real valuation pressure lies in the "future." Even using the median guidance revenue of $140 million, the forward price-to-sales ratio is still about 23 times. The market is not paying today's price, but the price perfectly delivered in FY2027.

So, a stock price that has already risen fivefold and now accounts for a threefold increase in advance—how much margin of safety does it leave for those who come after?

The turning point showed hard data for the first time, but prices were ahead of the curve

According to the report's framework, AEHR is on the 'eve of explosion' (pre_breakout): commercialization has long been underway, thousands of installed machines and mature product lines exist, but sustained profitability has yet to be confirmed.

Now, this assessment has subtly loosened—Q4 revenue rebounded from a low of about $10 million in previous quarters to $18.8 million, turning positive for the first time. The first turning point is no longer just the numbers in the guidance, but the actual financial report.

The technical side is also backing the bulls

The 50-day moving average is at $93.82, well above the 200-day moving average at $50.73, indicating a strong long-term upward trend. The market clearly agrees with this story.

But perhaps his agreement was too thorough. When stock prices have already reached the target prices most brokers have just raised, the premium paid by the market for the "turning point" itself becomes the biggest risk.

In a narrow gap that giants look down on, it has done what others don't

Semiconductor testing equipment is a market dominated by industry giants. Teradyne's 2024 revenue is about $2.8 billion, Advantest's about $4.5 billion, both monopolizing electrical parameter testing for SoC and memory, with price-to-sales ratios of only 5 to 12 times.

AEHR's way of life is to "avoid the sharp edge." It does not compete with giants for general-purpose ATE, but instead enters the narrow gap of full-wafer aging—integrating high-temperature, high-pressure reliability baking machines with electrical testing on a single wafer-level platform.

This is especially critical for SiC, GaN power devices, and photonic devices, as these new devices demand near-stringent reliability. Specialized manufacturers like FormFactor and Cohu are more about complementing it upstream and downstream rather than competing head-on.

The moat can be used as an analogy

The giants build large equipment for general hospitals, while AEHR builds precision instruments specialized in treating rare diseases. There aren't many patients, but you can't live without it.

But on the other side of the narrow gap is the ceiling. This niche segment is limited in scale. If a giant steps in and extends downward, how long can AEHR's differentiation last?

The ceiling is not low, but the market share is still very thin

The global semiconductor testing equipment market (including ATE, probe cards, sorters, and burn-in systems) is estimated to be in the $70 to $80 billion range, with burn-in and reliability test subsystems accounting for about 5% to 8%. The explosion of AI data centers, electric vehicles, and SiC/GaN is continuously expanding this pie.

The addressable market (SAM) that AEHR can truly serve is roughly in the $1.5 to $3 billion range. Based on FY2026's $50 million revenue, its current penetration rate is only in the single digits.

This is both a space for imagination and a harsh reality: if the guidance is fulfilled, the market share could double; Even so, it is still far from becoming a "platform-level market leader," with its growth relying entirely on a few major clients.

For the first time, hard data has taken the side of the story

The weight of bullish logic is no longer just about PPTs, but backed by real quarterly reports:

▲ Bull Case

After a fivefold increase, the good news is almost entirely in the price

The core of the bear market isn't "the company is bad," but "the stock price is too high, and the good news comes too early":

▼ Bear Case

Next, the guidelines will be self-validated quarterly

The good story is told, and now it's time to deliver on the promise. AEHR's stock price rhythm is firmly dominated by the following factors:

•	FY2027 Q1 Financial Report (expected to be released in October 2026): The first key window for guidance fulfillment, where direction determines sentiment
•	Actual conversion and revenue recognition rhythm of approximately $100.6 million in order backlog: Positive throughout FY2027
•	Rumored confirmation and repurchase at the company level for major AI accelerator orders: timing unclear, but if confirmed positively, it is a positive outcome
•	Industry-level cycle confirmation of SiC/GaN and AI data center testing demand: second half of 2026 to 2027, neutral to positive

From the bottom to the positive quarterly report, the stock price jumped a full fivefold

If you compare stock price with fundamentals, you'll see a typical 'expectation-driven' market. FY2025 annual revenue was still $59 million, but entering FY2026, it declined steadily, with quarterly revenues dropping to a low of about $10 million.

At the worst time of the fundamentals, the stock price actually surged, rising about 501% over 12 months. What the market is betting on is a reversal after the cycle bottoms out.

The bet was half paid last week

Q4 revenue rebounded to $18.8 million, a 33% year-over-year increase and turned profitable, accompanied by record orders and tripling guidance, confirming the "turning point" narrative.

But history also reminds us of another side—during the SiC concept boom from 2021 to 2022, AEHR experienced a round of surging expectations followed by a pullback where all the positive news was exhausted. Today's form is so similar to back then.

⚠️ Risk Notice • Valuations have been drastically stretched, with a price-to-sales ratio of about 64 times; guidance below expectations may trigger a sharp correction • Quarterly revenue needs to triple in size, but ramp-up capacity and delivery execution risks are high • With high customer concentration, even a single large order fluctuation can severely impact performance • Strong semiconductor cyclical factors, slowing AI capital expenditure will impact testing demand • Beta 3.18, up about 501% this year, with significant risk of mean reversion in the short term

🟡 Neutral The turning point is supported by hard data, but the stock price has already been priced in optimistic expectations that guidance will be perfectly realized.

💬 Discussion The positive news is highly likely to be realized, so be cautious when chasing highs; Its real-time buy and sell prices can be viewed via AEHR on the official WeChat account.

Data source

•	Source: NextPick real-time snapshot + company FY2026 Q4 and full-year earnings and FY2027 guidance (8-K) + SEC announcement + broker ratings and market reports from mainstream financial media.